108 related articles for article (PubMed ID: 9779875)
1. New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction.
Kantarjian H
Semin Hematol; 1998 Jul; 35(3 Suppl 4):1-2. PubMed ID: 9779875
[No Abstract] [Full Text] [Related]
2. [Topoisomerase I inhibitors].
Bornkessel B
Med Monatsschr Pharm; 1997 May; 20(5):114-6. PubMed ID: 9221294
[No Abstract] [Full Text] [Related]
3. The use of topoisomerase I inhibitors in multiple myeloma.
Kraut EH; Ju R; Muller M
Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M
Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895
[No Abstract] [Full Text] [Related]
5. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis by topotecan: implications for the treatment of leukemia.
Seiter K
Semin Hematol; 1998 Jul; 35(3 Suppl 4):22-5. PubMed ID: 9779878
[TBL] [Abstract][Full Text] [Related]
7. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
8. Natural inhibitors of DNA topoisomerase I with cytotoxicities.
Han HJ; Tan NH; Zeng GZ; Fan JT; Huang HQ; Ji CJ; Jia RR; Zhao QS; Zhang YJ; Hao XJ; Wang LQ
Chem Biodivers; 2008 Jul; 5(7):1364-8. PubMed ID: 18649302
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and antiangiogenic therapy in hematologic malignancies.
Dong X; Han ZC; Yang R
Crit Rev Oncol Hematol; 2007 May; 62(2):105-18. PubMed ID: 17188504
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I interactive agents.
Kirstein MN; Turner PK; Stewart CF
Cancer Chemother Biol Response Modif; 2002; 20():99-123. PubMed ID: 12703202
[TBL] [Abstract][Full Text] [Related]
11. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
Pourquier P; Pommier Y
Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase I interactive agents.
Stewart CF
Cancer Chemother Biol Response Modif; 2001; 19():85-128. PubMed ID: 11686040
[TBL] [Abstract][Full Text] [Related]
13. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
14. DNA topoisomerase i as a transcription protein and a lethal cellular toxin.
Lotito L; Ferri F; Russo A; Capranico G
Ital J Biochem; 2007 Jun; 56(2):122-9. PubMed ID: 17722653
[TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase expression in tumors--a novel target for chemotherapy.
Rubin EH
Hum Pathol; 2000 Jun; 31(6):631-2. PubMed ID: 10872653
[No Abstract] [Full Text] [Related]
16. Antibodies and hematologic malignancies.
Smith MR
Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
[TBL] [Abstract][Full Text] [Related]
17. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
18. The clinical pharmacology of topoisomerase I inhibitors.
Abang AM
Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
[TBL] [Abstract][Full Text] [Related]
19. [NB 506].
Lansiaux A; Bailly C
Bull Cancer; 1999 Mar; 86(3):255-8. PubMed ID: 10210758
[No Abstract] [Full Text] [Related]
20. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
McCluskey AG; Boyd M; Gaze MN; Mairs RJ
Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]